Compare Johnson & Johnson (JNJ) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Procter & Gamble Co — how do they compare? Johnson & Johnson trades at $258.89 (market cap $618.09B), while Procter & Gamble Co trades at $151.06 (market cap $349.77B). The key difference: Johnson & Johnson is the larger of the two by market cap, and Procter & Gamble Co pays the higher dividend (2.89%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Procter & Gamble Co for 131 Days on average.
| JNJ | PG | |
|---|---|---|
Market Cap | $618.09B | $349.77B |
Volume | 6,050,983 | 10,055,825 |
Sector | Health | Consumer Staples |
52-Week High | $278.43 | $167.18 |
52-Week Low | $186.00 | $138.10 |
Typical Hold Time | 129 Days | 131 Days |
Enterprise Value | $646.37B | $375.61B |
Dividend Yield | 2.09% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Procter & Gamble (PG) trades at $147.82, down 0.4% on the day, showing resilience amid market volatility. The stock maintains a bullish technical signal with strong moving average support and has consistently beaten earnings estimates in recent quarters. PG demonstrates robust fundamentals with $84.28B revenue, 18.44% net margin, and steady dividend payments, though valuation multiples remain elevated versus peers.
PG offers stable growth with dividend reliability but faces premium valuation concerns. The 8.3% upside to consensus target of $160.13 suggests moderate potential, while competitive pressures and soft demand outlook present headwinds. Institutional ownership trends show mixed positioning, requiring careful monitoring of margin sustainability and consumer spending patterns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
